ASLAN Pharmaceuticals to Present Two Posters on Varlitinib at ASCO
May 17, 2018 02:25 ET
|
ASLAN Pharmaceuticals Limited
SINGAPORE, May 17, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (ASLAN, 6497.TT) (Nasdaq:ASLN), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia...
TESARO Announces Presentations of Abstracts at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
May 16, 2018 17:15 ET
|
TESARO, Inc.
Investor briefing to be webcast from Chicago on Monday, June 4, 2018 at 6:15PM CT WALTHAM, Mass., May 16, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical...
Jounce Therapeutics to Present Data from Ongoing ICONIC Trial of JTX-2011 at the 2018 American Society of Clinical Oncology Annual Meeting
May 16, 2018 17:01 ET
|
Jounce Therapeutics, Inc.
ICONIC Target Enrollment Met Across Four Combination Cohorts Company to Host Investor Event and Live Webcast on Monday, June 4 CAMBRIDGE, Mass., May 16, 2018 (GLOBE NEWSWIRE) -- Jounce...
Oncology Venture Announces Abstracts on Three Pipeline Products Selected for 2018 ASCO Clinical Meeting
May 16, 2018 17:00 ET
|
2X Oncology, Inc.
HOERSHOLM, Denmark and CAMBRIDGE, Mass., May 16, 2018 (GLOBE NEWSWIRE) -- Oncology Venture AB (OV:ST) (“OV” or the “Company”) announced today that three abstracts detailing clinical trials of its...
Myxoid/Round Cell Liposarcoma Data with NY-ESO and MAGE-A10 Study Update to be Presented at American Association for Clinical Oncology (ASCO) Annual Meeting
May 16, 2018 17:00 ET
|
Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORD, U.K., May 16, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will release updated data from ongoing...
Jounce Therapeutics Reports First Quarter 2018 Financial Results
May 09, 2018 06:30 ET
|
Jounce Therapeutics, Inc.
- Preliminary efficacy data from Phase 1/2 ICONIC trial to be presented as an oral presentation at the 2018 ASCO Annual Meeting - - Company to host conference call and webcast today at 8:00 AM ET - ...
STUDY OF T CELL MEDIATED IMMUNITY FROM COMBINATION OF PV-10 AND IMMUNE CHECKPOINT BLOCKADE IN MURINE MELANOMA MODELS PUBLISHED IN PLOS ONE
April 30, 2018 09:00 ET
|
Provectus Biopharmaceuticals Inc.
FOR IMMEDIATE RELEASE Combinations with PV-10 included + anti-CTLA-4; + anti-PD-1; + anti-PD-L1; and, + anti-PD-1 + Treg depletion Data provided basis for ongoing Phase 1b/2 study of PV-10 in...
PROVECTUS BIOPHARMACEUTICALS AND PEDIATRIC ONCOLOGY EXPERIMENTAL THERAPEUTICS INVESTIGATORS' CONSORTIUM (POETIC) ANNOUNCE ACCEPTANCE OF PV-10 POSTER PRESENTATION AT AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING
April 25, 2018 16:00 ET
|
Provectus Biopharmaceuticals Inc.
FOR IMMEDIATE RELEASE Preclinical pediatric cancer research undertaken at POETIC member institutions Alberta Children’s Hospital (Canada) and Memorial Sloan Kettering Cancer Center KNOXVILLE,...
aTyr Pharma Announces Fourth Quarter and Year-End 2017 Operating Results and Provides Corporate Update
March 19, 2018 16:05 ET
|
aTyr Pharma, Inc.
SAN DIEGO, March 19, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological...
aTyr Pharma Announces Poster Presentation at ASCO-SITC Clinical Immuno-Oncology Symposium
December 21, 2017 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Dec. 21, 2017 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of immuno-modulatory protein therapeutics to treat...